Revenue Recognition (Tables)
|
6 Months Ended |
Jun. 30, 2025 |
|---|
| Revenue Recognition |
|
| Schedule of disaggregation of revenues by payer types |
| | | | | | | | | | | | | | | Three months ended | | Six months ended | | | June 30, | | June 30, | | | 2025 | | 2024 | | 2025 | | 2024 | | | | (in thousands) | Insurance carriers | | $ | 516,987 | | $ | 384,128 | | $ | 989,635 | | $ | 725,156 | Laboratory partners | | | 22,169 | | | 22,254 | | | 43,001 | | | 42,530 | Patients | | | 7,444 | | | 6,969 | | | 15,795 | | | 13,406 | Total revenues | | $ | 546,600 | | $ | 413,351 | | $ | 1,048,431 | | $ | 781,092 |
|
| Schedule of total revenue by geographic area |
| | | | | | | | | | | | | | | | Three months ended | | Six months ended | | | | June 30, | | June 30, | | | | 2025 | | 2024 | | 2025 | | 2024 | | | | | (in thousands) | | United States | | $ | 537,801 | | $ | 404,872 | | $ | 1,030,107 | | $ | 764,285 | | Americas, excluding U.S. | | | 1,571 | | | 1,601 | | | 3,263 | | | 3,082 | | Europe, Middle East, India, Africa | | | 5,408 | | | 5,439 | | | 11,457 | | | 10,617 | | Asia Pacific and Other | | | 1,820 | | | 1,439 | | | 3,604 | | | 3,108 | | Total revenues | | $ | 546,600 | | $ | 413,351 | | $ | 1,048,431 | | $ | 781,092 | |
|
| Schedule of beginning and ending balances of accounts receivable and deferred revenues |
| | | | | | | | | Balance at | | | June 30, | | December 31, | | | 2025 | | 2024 | | | | (in thousands) | Assets: | | | | | | | Accounts receivable, net | | $ | 309,224 | | $ | 314,165 | Liabilities: | | | | | | | Deferred revenue, current portion | | $ | 21,560 | | $ | 19,754 | Deferred revenue, long-term portion (1) | | | 16,492 | | | 16,838 | Total deferred revenues | | $ | 38,052 | | $ | 36,592 |
|
| Schedule of changes in the balance of deferred revenues |
| | | | | | | | | Balance at | | | June 30, | | | 2025 | | | 2024 | | | (in thousands) | Beginning balance | | $ | 36,592 | | $ | 35,740 | Increase in deferred revenues | | | 20,369 | | | 14,826 | Revenue recognized during the period included in deferred revenues at the beginning of the period | | | (14,904) | | | (9,646) | Revenue recognized from performance obligations satisfied within the same period | | | (4,005) | | | (4,137) | Ending balance | | $ | 38,052 | | $ | 36,783 |
|